BRAF and metastatic melanoma: Survival varied significantly by the year of diagnosis with MBM due to the introduction of new therapeutic options (ICI, BRAF/MEKi) in Europe in 2016 and their full availability in Italy and Poland in 2017, when national programs for the systemic treatment of patients with metastatic melanoma started to become widely used.